The details of the Sanofi-Genzyme merger were leaked over the weekend, indicating that there will likely be a $74 cash component plus a CVR. A number of deals were announced this morning. The deal with the largest cash component was Beckman Coulter, another healthcare company.
Increased M&A, specifically the cash kind, is a big boost for the market but especially for the sector where it occurs. I remain of the firm belief that this cash will eventually filter into the healthcare sector, specifically the biotech industry. Right now it seems the cash is filtering just about everywhere else.